Journal
CLINICAL INFECTIOUS DISEASES
Volume 52, Issue -, Pages S290-S295Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir044
Keywords
-
Categories
Funding
- Food and Drug Administration
- Infectious Diseases Society of America
- AstraZeneca Pharmaceuticals
- Bio Merieux, Inc.
- Cepheid
- Gilead Sciences
- Intelligent MDX, Inc.
- Inverness Medical Innovations
- Roche Molecular Systems
Ask authors/readers for more resources
Acute exacerbations are significant events in the course of chronic obstructive pulmonary disease. Modern diagnostic techniques have revealed an infectious cause for the majority of exacerbations. Common respiratory viruses contribute to 25%-50% of exacerbations. Detection of viral nucleic acids in nasopharyngeal swab or sputum samples has become the preferred method to study viral exacerbations instead of viral cultures and serologic examination. Clinical application of such molecular detection requires additional studies to clarify interpretation of a positive result. Bacteria account for 25%-50% of exacerbations. Studies comparing molecular detection of bacteria in sputum with conventional culture techniques have shown that a substantial proportion of bacteria are not detected by the latter method. However, as with molecular viral detection, clinical application of molecular bacterial diagnosis requires additional studies. Although still faced with several challenges and requiring additional development, it is quite likely that molecular methods will become the preferred methods for determining the etiology of exacerbations of chronic obstructive pulmonary disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available